我国抗肿瘤药物研发现状与展望  

Current Status and Future Perspectives on Oncology Drug Discovery and Development in China

作　　者：黄敏 耿美玉 Min Huang;Meiyu Geng(State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China)

机构地区：[1]中国科学院上海药物研究所,原创新药研究全国重点实验室,上海201203

出　　处：《中国科学基金》2025年第1期91-98,共8页Bulletin of National Natural Science Foundation of China

摘　　要：基于国家自然科学基金委员会第373期双清论坛“临床问题驱动的肿瘤研究新范式”会议内容,本文总结了我国抗肿瘤药物的研发现状,包括近十年来我国抗肿瘤新药研发取得的显著成果以及当前领域面临的挑战,并在此基础上展望了未来有望催生我国抗肿瘤新药研发进一步取得原创突破的着力点和发展方向,以期对我国抗肿瘤药物研究起到指导作用。The discovery and development of oncology drugs in China has experienced unprecedented progress over the past three decades.This article summarizes the significant achievements being made in the discovery and development of anticancer therapies in China in the recent decade.We also identify the challenges the field is facing and propose the future directions that are expected to promote further breakthroughs in the development of innovative anticancer therapies in China.With this article,we hope to provide guidance for the field.

关 键 词：抗肿瘤药物 新药研发 分子靶向药物 免疫治疗 精准治疗 抗肿瘤靶点 

分 类 号：R979.1[医药卫生—药品]